← Search & browse all drugs

lutetium (177Lu) vipivotide tetraxetan

V10XX05

Forms & Strengths

Solution for intravenous infusion: 1,000 MBq/mL (1 GBq/mL) at the time of calibration

Adult Dosing

7.4 GBq (200 mCi) intravenously every 6 weeks for up to 6 doses
Pre-medication with antiemetics recommended prior to administration
Dose modification (reduction, delay, or permanent discontinuation) required for specific adverse reactions (hematologic, renal, hepatic)

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy

Mechanism of Action

Radioligand therapeutic agent consisting of a PSMA-binding ligand coupled to the beta-minus emitting radioisotope lutetium-177
Binds to PSMA-expressing cells (including prostate cancer cells), delivering beta-particle radiation to the target cells and surrounding microenvironment to induce DNA damage and cell death

Contraindications

None known

Adverse Reactions

Myelosuppression (anemia, thrombocytopenia, leukopenia, lymphopenia)
Fatigue
Nausea
Dry mouth
Vomiting
Constipation
Acute kidney injury
Infusion-related reactions

Drug Interactions

Concomitant use with strong CYP inhibitors or inducers has not been formally studied but pharmacokinetic interactions are unlikely given elimination via the renal system
Avoid concurrent use of nephrotoxic drugs to minimize additive renal toxicity

Curated Content: Needs Vetting Before Put to Clinical Use